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Introduction: Studies investigating the association of psychosocial fac-
tors involving depression, anxiety and lower health-related quality of
life (HRQoL) with clinical outcomes in patients with early stage chronic
kidney disease (CKD) are lacking. This analysis describes the baseline
characteristics and clinical outcomes of participants in the Tasmanian
CKD study. This prospective cohort study aims to examine the relative
influence of both biomedical and psychosocial factors on disease pro-
gression and clinical outcomes in adults with eGFR<30 mls/min/1.73m2
not on renal replacement therapy (RRT).
Methods: Overall, 222 adults aged >18 years provided data at
baseline (2010-2012, 2016-2018). Of these, 179 participants attended a
baseline clinic where self-report measures including depression (9-
item Patient Health Questionnaire; PHQ-9), anxiety (Beck Anxiety
Inventory; BAI) and HRQoL (Kidney Disease Quality of Life–Short
Form; KDQOL-SF) were completed. Study outcome was defined as a
composite of initiation of RRT or death. Associations between psy-
chosocial factors at baseline and study outcome were assessed using
Spearman’s rho.
Results: Overall, participants were predominantly male (61%, n=135)
with a mean age of 72.011.6 years. Mean serum creatinine was
253.281.7 mmol/L with mean eGFR 21.45.3 mls/min/1.73m2. Mean
(SD) time to follow-up was 471 (290) days. At follow-up, 60 (27%)
participants experienced an outcome (34 initiated RRT and 26 deaths).
At baseline, prevalence of clinical depression (PHQ-9 score $10) was
13.5% and prevalence of moderate/severe anxiety (BAI score $16)
was 12%. From the KDQOL-SF, physical component summary (PCS)
was 38.310.4 and mental component summary (MCS) was 51.010.3.
MCS was significantly lower in participants who experienced an
outcome than those who did not (48.41.5 versus 52.00.9, p<0.04).
PCS was not significantly different between groups (37.01.5 versus
38.81.0, p>0.05). Lower scores on the MCS (r=-0.19) and several
subscales of the KDQOL-SF including symptoms/problems (r=-0.17),
effects of kidney disease on daily life (r=-0.17) and burden of kidney
disease (r=-0.31) were significantly associated with the study outcome
(all p<0.05).
Conclusions: Results indicate substantial psychosocial morbidity in
adults with CKD not on RRT. Further, lower HRQoL, involving both
psychological and physical domains, appear to be indicators of initia-
tion of RRT or death. Identifying modifiable risk factors is an important
first step in reducing the risk of RRT or premature death in this patient
population and improving quality of life.
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Introduction: Little is known about the association between medication
burden and patient-reported outcomes in adults with advanced chronic
kidney disease (CKD) not on renal replacement therapy (RRT). We
aimed to examine the association between actual medication burden
(the number of medications and regimen complexity) with perceivedKidney International Reports (2019) 4, S1–S437burden of medication and health-related quality of life (HRQoL) in
adults with CKD (eGFR<30 mL/min/1.73m2) not on RRT.
Methods: Participants were recruited through their treating physicians.
Patient characteristics including laboratory and medical information
were collected during an interview. Actual medication burden was
assessed using the number of medications and medication regimen
complexity, which was measured using the 65-item medication regimen
complexity index (MRCI). Perceived burden of medication was self-
reported by participants using a short questionnaire. The Kidney Dis-
ease and Quality of Life Short Form (KDQoL-SF), which has disease-
specific and generic components (SF-36), was used to measure HRQoL.
Linear regression models adjusted for age, gender, comorbidities, and
eGFR were applied to examine associations between medication burden
and patient outcomes.
Results: Overall, 101 patients, predominantly men (65%), with a
mean (SD) age of 72 (11) years and eGFR of 22 (6.2) mL/min/1.73m2,
were included. The average number of medications per participant
was 8 (3.6), with 41 (40%) taking $9 medications per day, and the
median (IQR) MRCI was 18.5 (14-34). The mean physical and mental
component summary scores for the included patients were 46 (20)
and 56 (19), respectively. The number of medications (b=0.35;
p<0.05) and MRCI (b=0.36; p<0.05) were associated with perceived
burden of therapy after adjustment. The number of medications (b=-
0.27; p<0.05) and MRCI (b=-0.33; p<0.05) were negatively associated
with the cognitive function subscale of the KDQoL. The physical
component summary of the SF36 was also associated with the number
of medications (b=-0.48; p<0.01) and MRCI (b=-0.48; p<0.01) after
adjustment.
Conclusions: Patients’ perceived burden of therapy was reflective of
their actual medication burden. Moreover, individuals with a higher
medication burden were more likely to report lower physical health-
related quality of life and cognitive functioning.
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Introduction: Kidney disease accounts for a growing burden of disease,
particularly in low income countries. Despite a growing body of liter-
ature from resource limited settings, relatively little is known about the
epidemiology and etiology of acute and chronic kidney disease. With
the goal of improving patient management of specific diseases,
advancing understanding of the etiology and risk factors of kidney
disease, targeting prevention strategies addressing causes of disease and
building a foundation for an in-country transplantation program, we
aimed to implement a high quality and sustainable renal biopsy pro-
gram in Rwanda.
Methods: Beginning in 2013, we conducted a needs assessment to
establish existing clinical and laboratory equipment and consumables,
human resources, insurance coverage and treatments available in
Rwanda and the necessary procurement, training and policies required
to build a national renal pathology program. Engagement of govern-
ment officials, leadership at the University of Rwanda's teaching hos-
pitals and clinicians caring for kidney patients was established through
focus groups and meetings to plan implementation in alignment with
local priorities. Between 2014-2015, 4 trainers were recruited to build
capacity in tissue preparation, slide interpretation, clinical decisionS251
